These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 9492559)

  • 1. [Gadolinium-DTPA tolerance and clinical safety].
    Niendorf HP; Brasch RC
    Rontgenpraxis; 1997 Dec; 50(12):354-63. PubMed ID: 9492559
    [No Abstract]   [Full Text] [Related]  

  • 2. Gadolinium and kidney disease: are your patients at risk?
    Hollister D
    Nephrol Nurs J; 2008; 35(2):196-7. PubMed ID: 18472687
    [No Abstract]   [Full Text] [Related]  

  • 3. MR arthrography: pharmacology, efficacy and safety in clinical trials.
    Schulte-Altedorneburg G; Gebhard M; Wohlgemuth WA; Fischer W; Zentner J; Wegener R; Balzer T; Bohndorf K
    Skeletal Radiol; 2003 Jan; 32(1):1-12. PubMed ID: 12525938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.
    Shellock FG; Parker JR; Pirovano G; Shen N; Venetianer C; Kirchin MA; Spinazzi A
    J Magn Reson Imaging; 2006 Dec; 24(6):1378-85. PubMed ID: 17078095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notes on "Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent".
    Runge VM
    AJR Am J Roentgenol; 2008 Jun; 190(6):1433-4. PubMed ID: 18492887
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocarditis associated with polymyositis diagnosed by gadolinium-DTPA enhanced magnetic resonance imaging.
    Ohata S; Shimada T; Shimizu H; Murakami Y; Matsuno Y
    J Rheumatol; 2002 Apr; 29(4):861-2. PubMed ID: 11950039
    [No Abstract]   [Full Text] [Related]  

  • 8. Renal failure and gadolinium. The number of documented cases is rising.
    Prescrire Int; 2008 Oct; 17(97):205. PubMed ID: 19537311
    [No Abstract]   [Full Text] [Related]  

  • 9. [Magnetic-resonance urography: experience os using small doses of Gd-DTPA and amplification of contrast techniques].
    Sviridov NK; Napolov IuK
    Urologiia; 2002; (1):53. PubMed ID: 11877978
    [No Abstract]   [Full Text] [Related]  

  • 10. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
    Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
    Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudohypocalcemia after magnetic resonance imaging with gadolinium in patients with cirrhosis.
    Kefalas CH; Murray NG; Aguanno JJ; Dockery WD; Weinstein JS; Anderson K; Klintmalm GB
    Liver Transpl; 2004 Jan; 10(1):136-40. PubMed ID: 14755791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed contrast enhancement magnetic resonance imaging for the assessment of cardiac disease.
    Marcu CB; Nijveldt R; Beek AM; Van Rossum AC
    Heart Lung Circ; 2007 Apr; 16(2):70-8. PubMed ID: 17317312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intercellular imaging by a polyarginine derived cell penetrating peptide labeled magnetic resonance contrast agent, diethylenetriamine pentaacetic acid gadolinium.
    Guo YM; Liu M; Yang JL; Guo XJ; Wang SC; Duan XY; Wang P
    Chin Med J (Engl); 2007 Jan; 120(1):50-5. PubMed ID: 17254488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seizure after gadolinium administration.
    Hailemeskal B; Ilogu E; Khuc K; Curry C; Kelvas M
    Radiol Technol; 1999; 70(4):387. PubMed ID: 10101755
    [No Abstract]   [Full Text] [Related]  

  • 15. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 16. [Contrast-enhanced magnetic resonance imaging in the diagnosis of urinary tract disease].
    Shimanovskiĭ NL; Napolov IuK
    Vestn Rentgenol Radiol; 2005; (4):47-56. PubMed ID: 16353902
    [No Abstract]   [Full Text] [Related]  

  • 17. In reference to 3 Tesla delayed contrast magnetic resonance imaging evaluation of Meniere's disease.
    Naganawa S; Nakashima T
    Laryngoscope; 2008 Oct; 118(10):1904-5; author reply 1905. PubMed ID: 18827624
    [No Abstract]   [Full Text] [Related]  

  • 18. [Preparation of a novel targeted MR contrast agent Gd-DTPA-streptavidin and exploration of its reaction conditions].
    Liu X; Xu YK; Huang QL
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):15-7. PubMed ID: 14724085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic contrast enhanced MRI of mouse fibrosarcoma using small-molecular and novel macromolecular contrast agents.
    Ivanusa T; Beravs K; Medic J; Sersa I; Sersa G; Jevtic V; Demsar F; Mikac U
    Phys Med; 2007 Dec; 23(3-4):85-90. PubMed ID: 18061121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Modes for enhancing the efficiency of gadolinium chelates as contrast substances].
    Napolov IuK; Musatov SV
    Vestn Rentgenol Radiol; 2005; (1):58-62. PubMed ID: 16711249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.